Ipsen UK
Presence
Ipsen is one of the...
Ipsen is a company listed under the stock ticker IPN (FR).
Ipsen has a direct presence in 5 countries.Ipsen has 4 subsidiaries including Ipsen Iberica, Ipsen North America and Ipsen UK.
Executives
View the org chart displaying its 0 main executives
Most searched biographies at Ipsen UK
Popular executive movements at Ipsen
- Stewart Campbell, Executive Vice President, President, North America, will leave the company on May 13, 2024 (posted on May 2 2024).
- Keira Driansky will join the company as Executive Vice President and President of North America on May 13, 2024 (posted on May 2 2024).
- Pascal Touchon has joined the company as Independent Director (posted on September 4 2023).
Create your alert
to follow the executive moves at Ipsen UK.
Pharmaceuticals
Ipsen has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Ipsen UK
- Press Releases - Ipsen UK
- Ipsen shares results from innovative research partnership exploring young people’s attitudes to science - Ipsen UK
- Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼ (cabozantinib) in combination with OPDIVO® (nivolumab) via NHS Scotland, following SMC acceptance* - Ipsen UK
- New campaign launches to break down taboos around prostate cancer treatment side effects - Ipsen UK
- Ipsen and Mendelian Announce Landmark Partnership to Reshape Rare Disease Diagnosis using Pioneering MendelScan Technology - Ipsen UK
- Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼ (cabozantinib) in combination with OPDIVO® (nivolumab) via NHS Scotland, following SMC acceptance* - Ipsen UK
- Ipsen shares results from innovative research partnership exploring young people’s attitudes to science - Ipsen UK
- New campaign launches to break down taboos around prostate cancer treatment side effects - Ipsen UK
- Ipsen and Mendelian Announce Landmark Partnership to Reshape Rare Disease Diagnosis using Pioneering MendelScan Technology - Ipsen UK
- Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy - Ipsen UK
- View more press releases Close
Social media about Ipsen UK
- Ipsen UK on Wikipedia, Google News & Yahoo Finance
- Ipsen UK on LinkedIn, Twitter & YouTube
